Clinical trials: Diabetes Mellitus II
- Condition Diabetes Mellitus II
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Type II Diabetes
A Study to Assess the Bioequivalence of Fixed Dose Combination of HR20033 Relative to Co-administration of the Individual Components in Healthy Chinese Subjects
The trial is to assess the bioequivalence between HR20033 FDC tablet and co-administration of SHR3824 tablets and metformin XR tablets.
- Trial name
- NCT05108350
- Testing
- T1: FDC 5/500 mg; R1+R: SHR3824 5 mg + Metformin 500 mg XR, T2: FDC 5/1000 mg; R2+R: SHR3824 5 mg + two Metformin 500 mg XR
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Diabetes Mellitus, Type II
A Clinical Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.5/1000 mg in Healthy Male Volunteers
This study is a randomized, open-label, single dose, 2-way crossover study to compare the pharmacokinetic characteristics of CKD-395 0.5/1000 mg in healthy male volunteers.
- Trial name
- NCT02565368
- Testing
- Duvie Tab. 0.5mg, Glucophage XR Tab. 1000mg, CKD-395 0.5/1000mg
- Where
- South Korea
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Diabetes Mellitus, Type II
A Clinical Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.25/500mg in Healthy Male Volunteers
This study is a randomized, open-label, single dose, 2-way crossover study to compare the pharmacokinetic characteristics of CKD-395 0.25/500 mg in healthy male volunteers.
- Trial name
- NCT02685774
- Testing
- Duvie Tab. 0.5mg, Glucophage XR Tab. 500mg, CKD-395 0.25/500mg
- Where
- South Korea
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Type II Diabetes
Pharmacokinetics and Safety/Tolerability After Oral Administration of CKD-387 and D484 in Healthy Adults
Randomized, Open-label, Single-dose, Two-way Crossover Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability after Oral Administration of CKD-387 10/1000 mg and D484 10/1000mg in Healthy Adults
- Trial name
- NCT03646799
- Testing
- CKD-387, D484
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Type II Diabetes Mellitus
Study to Evaluate the Food Effect on Pharmacokinetics Profile and Safety of CKD-393
Study to evaluate the food effect on pharmacokinetic profiles and safety of CKD-393 in healthy volunteers
- Trial name
- NCT05274880
- Testing
- CKD-393
- Where
- South Korea
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Type II Diabetes
Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763
This study is a three part study to assess the safety and efficacy of LEZ763 on normal healthy volunteers and patients with Type 2 Diabetes.
- Trial name
- NCT01619332
- Testing
- Sitagliptin, LEZ763
- Where
- 6 sites in United States
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus
Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of JTT-252
The purpose of this study is to evaluate the safety, tolerability, and PK of single oral doses of JTT-252 and the effect of food on the PK of JTT-252 in healthy subjects, and to evaluate the safety, tolerability, PK and PD of…
- Trial name
- NCT02120976
- Testing
- JTT-252
- Where
- 2 sites in United States
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Shionogi Inc.
Obesity
Phase II Clinical Study of HDM1005 Injection in Obese Adults Without Diabetes Mellitus
It is a multicenter, randomized, double-blind, placebo-controlled phase II clinical trial to evaluate the efficacy and safety of HDM1005 injection in nondiabetic obese adults.
- Trial name
- NCT06886126
- Where
- China
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Type II Diabetes Mellitus
Pharmacokinetics and Safety/Tolerability of CKD-379
A study to compare the pharmacokinetics and safety/tolerability between CKD-379 tablet and D759, D745, D150 combination
- Trial name
- NCT05719155
- Testing
- CKD-379, D759+D745+D150
- Where
- South Korea
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Type II Diabetes Mellitus
Study to Evaluate if Exposure to Drug is Impacted in Participants With Renal Insufficiency
This is an open-label, single-dose, Phase 1 clinical study designed to evaluate the effect of renal impairment on the pharmacokinetics (PK) of GL0034, a long-acting GLP-1 receptor agonist.
- Trial name
- NCT07385547
- Testing
- GL0034
- Where
- 3 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Sun Pharmaceutical Industries Limited
Diabetes Mellitus, Type II
A Clinical Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.25/750 mg in Healthy Male Volunteers
This study is a randomized, open-label, single dose, 2-way crossover study to compare the pharmacokinetic characteristics of CKD-395 0.25/750 mg in healthy male volunteers.
- Trial name
- NCT02627027
- Testing
- Duvie Tab. 0.5mg, Glucodaun OR Tab. 750mg, CKD-395 0.25/750mg
- Where
- South Korea
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Type II Diabetes Mellitus
Clinical Study to Compare the Pharmacokinetic Characteristics and Safety Between CKD-380 10mg and D308 10mg
This study is an open-label, randomized, fasted, single-dose, 2-way crossover study to compare the pharmacokinetic characteristics and safety between CKD-380 10mg and D308 10mg in healthy male adults.
- Trial name
- NCT03601910
- Testing
- D308 10mg Tab., CKD-380 10mg Tab.
- Where
- South Korea
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Type II Diabetes Mellitus
A Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of Oral HMS5552 in Healthy Volunteers
The objectives of this study is to determine the safety profiles, tolerability, pharmacokinetics and pharmacodynamics of HMS5552 following single ascending doses in healthy adult subjects.
- Trial name
- NCT01952535
- Testing
- HMS5552
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Hua Medicine Limited
Diabetes Mellitus, Type 2, Healthy
Effect of Empagliflozin Kinetics on Renal Glucose Reabsorption in Patients With Type II Diabetes and Healthy Controls
Single center, 14-day, open-label trial to examine the effect of 25 mg q.d. empagliflozin on kinetics of renal glucose reabsorption in patients diagnosed with type 2 diabetes mellitus and healthy controls
- Trial name
- NCT01867307
- Testing
- Empagliflozin, BI 10773
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Type II Diabetes Mellitus
Safety And Efficacy Of Empagliflozin In Pakistani Muslim Population With Type Ii Diabetes Mellitus
To compare the safety and efficacy of empagliflozin versus other treatments in Pakistani Muslim population with type II diabetes mellitus.
- Trial name
- SAFE-PAK (NCT04665284)
- Testing
- Empagliflozin, Usual care group
- Where
- 11 sites in Pakistan
- Volunteers
- 244 people, healthy volunteers welcome
- Sponsor
- Getz Pharma
Diabetes Mellitus, Type II
Single Dose Escalation Study of PF-05190457 in Healthy Volunteers
PF-05190457 is a novel compound proposed for the treatment of Type 2 diabetes mellitus. The purpose of the study is to evaluate the safety and tolerability of PF-05190457 after administration of a single dose to healthy…
- Trial name
- NCT01247896
- Testing
- PF-05190457
- Where
- Belgium
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Pfizer
Intradermal Injections
A Pilot Study to Assess the Safety, PK and PD of Insulin Injected Via MicronJet or Conventional Needle
The purpose of this study is to compare glucose pharmacokinetics and insulin pharmacodynamics injected via the MicronJet in comparison with a conventional needle.
- Trial name
- MicronJet (NCT00602914)
- Testing
- MicronJet
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- NanoPass Technologies Ltd
Diabetes Mellitus, Type 2, Healthy Males
A First in Human, Single Dose, Safety and Tolerability Study of MKC253 Inhalation Powder in Healthy Adult Males
26 subjects will be enrolled into 5 different dose groups. The trial will consist of a screening, a dosing and a follow-up visit.
- Trial name
- NCT00475371
- Testing
- MKC253 Inhalation Powder
- Where
- Netherlands
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Mannkind Corporation
Type 2 Diabetes Mellitus
Glycemic Control, Safety and Tolerability of TC-6987 Monotherapy in Type 2 Diabetes Mellitus
TC-6987 is a selective nicotinic α-7 receptor ligand (open channel stabilizer) that has demonstrated potent anti-inflammatory/antioxidant properties in animal models.
- Trial name
- NCT01293669
- Testing
- TC-6987
- Where
- 18 sites in United States
- Volunteers
- 440 people, healthy volunteers welcome
- Sponsor
- Targacept Inc.
Diabetes Mellitus, Type II
Investigate the Effect of Food on the Pharmacokinetic Characteristics of CKD-395 in Healthy Male Volunteers
This study is A randomized, open-label, single dose, 2-way crossover study to investigate the effect of food on the pharmacokinetic characteristics of CKD-395 in healthy male volunteers.
- Trial name
- NCT02648854
- Testing
- CKD-395 0.5(Lobeglitazone)/1000(Metformin)mg 1T
- Where
- South Korea
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical